Company Profile

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE480.00-0.6 (-0.12 % )
PREV CLOSE (Rs.) 480.60
OPEN PRICE (Rs.) 488.00
BID PRICE (QTY) 479.10 (131 )
OFFER PRICE (QTY) 480.00 (47 )
VOLUME 4748
TODAY'S LOW / HIGH (Rs.)478.55 488.00
52 WK LOW / HIGH (Rs.)87.05 525.25
NSE479.60 -0.85 (-0.18 % )
PREV CLOSE(Rs.) 480.45
OPEN PRICE (Rs.) 490.00
BID PRICE (QTY) 479.60 (24 )
OFFER PRICE (QTY) 480.00 (195 )
VOLUME 55622
TODAY'S LOW / HIGH(Rs.) 479.20 490.00
52 WK LOW / HIGH (Rs.)87.6 525.6

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.52
TTM EPS (Rs.) 11.68
P/E Ratio 41.33
Book Value (Rs.) 36.49
Face Value (Rs.) 1
MCap (Rs. in Mn) 122942.15
Price/Earning (TTM) 37.50
Price/Sales (TTM) 13.14
Price/Book (MRQ) 13.23
PAT Margin (%) 32.39
ROCE (%) 46.23
Incorporation Year : 2018

Management Info :

Venkateswarlu Jasti - Chairman Venkateswarlu Jasti - Managing Director

Registered Office :

Address : #8-2-334 I, S D E Serene Chambers,6th Floor Road No. 5,Avenue 7, Banjara Hills ,
Hyderabad,
Telangana-500034

Phone : 040 - 2354 9414/ 3311/ 3315

Website : www.suvenpharm.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
10Feb02-10-2021$Suven Pharmaceuticals informs about outcome of board meeting Suven Pharmaceuticals inform
Suven Pharmaceuticals has informed that the Board of Directors of the company, at its meeting held today February 10, 2021, approved the following along with other business matters: Took on record and approved the attached Un-audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and nine months ended 31st December, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Reports of the Statutory Auditors. The Board has also declared an interim dividend of Re 1.00 per equity share of face value of Re 1 each for the year 2020-2021. The Board approved the Record Date, 18th February, 2021 notified by the Company for the purpose of payment of interim dividend to the eligible shareholders. The above said dividend will be paid on or before 11th March, 2021.

The above information is a part of company’s filings submitted to BSE.

Suven Pharmaceuticals has informed that the Board of Directors..
03Feb02-03-2021$ Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Wednesday, The 10Th February, 2021 Board Meeting Intimation fo
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2021 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Wednesday, the 10th February, 2021 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): 1) The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and nine months ended December 31, 2020. 2) To consider declaration of Interim Dividend, if any, for the financial year 2020-21 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be 18th February, 2021, if considered and approved by the Board.
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of t..
03Feb02-03-2021$ Board to consider Q3 results & Interim Dividend on Feb 10, 2021 Board to consider Q3 result
Suven Pharmaceuticals Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on February 10, 2021, inter alia, to consider and approve the following matter(s): 1. The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and nine months ended December 31, 2020 (Q3). 2. To consider declaration of Interim Dividend, if any, for the financial year 2020-21 and related matters etc. Further note that TRADING WINDOW for dealing in the securities of the Company is already closed from January 01, 2021 as per PIT Code of the Company. Trading window will be opened from February 13, 2021.
Suven Pharmaceuticals Ltd has informed BSE that a Meeting of th..
31Oct10-31-2020$Suven Suven Pharmaceuticals informs about press release Suven Suven Pharmaceuticals
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Suven Pharmaceuticals has informed that it has enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and half-year ended September 30, 2020. The advertisements as appeared on October 31, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements.

The above information is a part of company’s filings submitted to BSE. 
Pursuant to Regulation 47 of the SEBI (Listing Obligations and..
07Jul07-07-2020$Suven Pharmaceuticals informs about confirmation certificate Suven Pharmaceuticals inform

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, Suven Pharmaceuticals has informed that it has enclosed the Confirmation Certificate issued by KFin Technologies, Registrar and Share Transfer Agents of the Company, for the quarter ended June 30, 2020.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 74(5) of SEBI (Depositories and Particip..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit976.352700.8
Gross Profit 1315.09 3575.9
Operating Profit 1429.994032.63
Net Sales 2749.338337.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 14581.20 (0.41%)
M.Cap ( in Cr)
31011.55
Sanofi India (BSE)
 8384.00 (0.69%)
M.Cap ( in Cr)
19239.78
Astrazeneca Pharma I (BSE)
 3527.60 (1.64%)
M.Cap ( in Cr)
8776.25
Piramal Enterprises (BSE)
 1967.80 (2.60%)
M.Cap ( in Cr)
43979.97
Orchid Pharma (BSE)
 1024.60 (5.00%)
M.Cap ( in Cr)
4182.05
Shareholding Pattern More
PROMOTERS 60 %
MUTUAL FUNDS/UTI 3.29 %
NON-INSTITUTION 29.3 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes